الرئيسية » أخبار » Clinical News

Clinical News

Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major pending approval by the EMA

  The Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency’s (EMA) committee responsible for human medicines, has recently adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product ”Deferasirox Mylan”, intended for the treatment of chronic iron overload due to blood transfusions in patients with ...

أكمل القراءة »

A milestone in the treatment of b-thalassaemia – The 1st gene therapy for Transfusion Dependent β-Thalassaemia wins approval in Europe

  Zynteglo, Bluebird Bio’s ex vivo gene therapy for β-thalassaemia, got a green light from the EMA for conditional marketing authorization making it the 1st gene therapy for patients with thalassaemia to win such an approval.  The one-time gene therapy has been approved for patients 12 years and older with ...

أكمل القراءة »